RFI - Bioequivalence studies for Rifampicinum + Isoniazidum, 300 mg + 150 mg, hard capsules
Opis zapytania
Dear,
TZF Polfa is developing a generic product for Rifampicinum + Isoniazidum, 300 mg + 150 mg, hard capsules. In connection with the above, we invite you to prepare a proposal for conducting bioequivalence studies in the manner described in the attached RFI Z82_5914_1.
Produkty
1. Conducting bioequivalence studies - 1 szt.
TZF Polfa is developing a generic product for Rifampicinum + Isoniazidum, 300 mg + 150 mg, hard capsules. In connection with the above, we invite you to prepare a proposal for conducting bioequivalence studies in the manner described in the attached RFI Z82_5914_1.
Produkty
1. Conducting bioequivalence studies - 1 szt.
Termin składania ofert
2026-04-30 10:00:00.0
Lokalizacja
A. Fleminga 2
03-176 Warszawa
03-176 Warszawa
Kategoria asortymentowa
Leki i produkty lecznicze
Dane nabywcy
Tarchomińskie Zakłady Farmaceutyczne "Polfa" Spółka Akcyjna
A. Fleminga 2
03-176 Warszawa
NIP: 5250000564
A. Fleminga 2
03-176 Warszawa
NIP: 5250000564
